Lubienski A, Simon M, Lubienski K, Gellissen J, Hoffmann R-T, Jakobs T F, Helmberger T
Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland.
Radiologe. 2007 Dec;47(12):1097-106, 1108. doi: 10.1007/s00117-007-1587-4.
In the last two decades image-guided interventional catheterizations and percutaneous ablative regional treatment procedures have revolutionized the therapy of nonresectable primary and secondary liver tumours. A distinction is made between chemoablative procedures and thermo- and radioablative procedures. The main chemoablative interventions are transarterial infusion chemotherapy (HAIC; hepatic arterial infusion chemotherapy) and transarterial (chemo-)embolization (TACE/TAE). The object of the transarterial treatment procedures is to deliver the highest possible concentration of a chemotherapy agent or combination of chemotherapy agents directly into the tumour by way of the blood vessels supplying it, while at the same time keeping the systemic effects of the drugs as small as possible. Transarterial chemoperfusion to the liver can be applied in the treatment of all primary and secondary hepatic tumours, but the main indications are hepatocellular carcinoma (HCC) and metastases from colorectal primary tumours.
在过去二十年中,图像引导下的介入导管插入术和经皮消融区域治疗程序彻底改变了不可切除的原发性和继发性肝肿瘤的治疗方法。化学消融程序与热消融和放射消融程序有所不同。主要的化学消融干预措施是经动脉灌注化疗(HAIC;肝动脉灌注化疗)和经动脉(化学)栓塞(TACE/TAE)。经动脉治疗程序的目的是通过供应肿瘤的血管将尽可能高浓度的化疗药物或化疗药物组合直接输送到肿瘤中,同时使药物的全身效应尽可能小。肝动脉化学灌注可用于治疗所有原发性和继发性肝肿瘤,但主要适应症是肝细胞癌(HCC)和结直肠癌原发性肿瘤的转移灶。